Literature DB >> 23836289

Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Lutfiye Demir1, Seyran Yigit, Hulya Ellidokuz, Cigdem Erten, Isil Somali, Yuksel Kucukzeybek, Ahmet Alacacioglu, Suna Cokmert, Alper Can, Murat Akyol, Ahmet Dirican, Vedat Bayoglu, Aysegul Akder Sari, Mustafa Oktay Tarhan.   

Abstract

This study aimed to investigate the prognostic and predictive effect of FOXP3+ Tregs together with clinicopathologic factors in locally advanced breast cancer (LABC) patients. The medical records of 101 LABC patients who received neoadjuvant chemotherapy (NAC) between 2005 and 2012 were evaluated retrospectively. The density of intratumoral FOXP3+ lymphocytes in paraffin-embedded tissues was assessed by immunohistochemical analyses in appropriate cases. The relationship with clinicopathologic features, prognosis and chemotherapy response was investigated. HR(-) and HER2(+) tumors tended to have higher pre-chemotherapy Tregs than HR(+) tumors, and significantly higher pathologic complete response (PCR) rates were observed in these patients. Treg decline after NAC was associated with better pathological response rates. Lower intratumoral infiltration of FOXP3+ Tregs after NAC (<3.4/HPF) was significantly associated with higher PCR rates for breast, and close to the significance limit for total (or both for breast and axillary) PCR rates (PCR for breast: 25 vs. 2.9 % for low vs. high Treg, p = 0.001; PCR for breast + axillary tissue: 13.9 vs. 0 %, p = 0.05). Despite better PCR rates, patients with high intratumoral Treg infiltrates (≥11.5/HPF) before chemotherapy had significantly shorter overall survival than patients with low Treg infiltrates (<11.5/HPF). Cox multivariate regression analyses demonstrated that the density of Treg infiltration before chemotherapy was the strongest predictor for survival. This study established the predictive and prognostic effect of intratumoral FOXP3+ Tregs in LABC patients. To predict clinical outcome, evaluation of FOXP3+ Tregs in tumoral tissues before and after NAC should be considered for these high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836289     DOI: 10.1007/s10585-013-9602-9

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  47 in total

1.  p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Ye Xu; Lihua Yao; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Benyao Lin; Youyong Lu; Yuntao Xie
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

Review 2.  Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.

Authors:  Gunter von Minckwitz; Sibylle Loibl; Andrea Maisch; Michael Untch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

3.  The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer.

Authors:  Esther M de Kruijf; Johanna G H van Nes; Anita Sajet; Quirijn R J G Tummers; Hein Putter; Susanne Osanto; Frank M Speetjens; Vincent T H B M Smit; Gerrit Jan Liefers; Cornelis J H van de Velde; Peter J K Kuppen
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 4.  Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

Authors:  P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

5.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

6.  Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

Authors:  M Colleoni; G Viale; D Zahrieh; L Bottiglieri; R D Gelber; P Veronesi; A Balduzzi; R Torrisi; A Luini; M Intra; S Dellapasqua; A Cardillo; R Ghisini; G Peruzzotti; A Goldhirsch
Journal:  Ann Oncol       Date:  2007-11-06       Impact factor: 32.976

7.  The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Authors:  M E Straver; E J Th Rutgers; S Rodenhuis; S C Linn; C E Loo; J Wesseling; N S Russell; H S A Oldenburg; N Antonini; M T F D Vrancken Peeters
Journal:  Ann Surg Oncol       Date:  2010-04-06       Impact factor: 5.344

Review 8.  Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.

Authors:  J Mathew; K S Asgeirsson; K L Cheung; S Chan; A Dahda; J F R Robertson
Journal:  Eur J Surg Oncol       Date:  2008-05-23       Impact factor: 4.424

Review 9.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Authors:  Darryl A Oble; Robert Loewe; Ping Yu; Martin C Mihm
Journal:  Cancer Immun       Date:  2009-04-02

10.  Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Authors:  Silvia Darb-Esfahani; Sibylle Loibl; Berit M Müller; Marc Roller; Carsten Denkert; Martina Komor; Karsten Schlüns; Jens Uwe Blohmer; Jan Budczies; Bernd Gerber; Aurelia Noske; Andreas du Bois; Wilko Weichert; Christian Jackisch; Manfred Dietel; Klaus Richter; Manfred Kaufmann; Gunter von Minckwitz
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more
  22 in total

1.  Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.

Authors:  Rosemarie Krupar; Katharina Robold; Doris Gaag; Gerrit Spanier; Marina Kreutz; Kathrin Renner; Claus Hellerbrand; Ferdinand Hofstaedter; Anja K Bosserhoff
Journal:  Virchows Arch       Date:  2014-07-16       Impact factor: 4.064

2.  Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.

Authors:  Linda Hertlein; Thomas Kolben; Aurelia Vattai; Nadine Kremer; Sarah Meister; Susanne Beyer; Lucia Keilmann; Anna Hester; Mina Temelkov; Helene Heidegger; Elisa Schmoeckel; Mirjana Kessler; Sven Mahner; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-05       Impact factor: 4.553

3.  The distribution of cutaneous metastases correlates with local immunologic milieu.

Authors:  Joshua M Schulman; Mariela L Pauli; Isaac M Neuhaus; Roberto Sanchez Rodriguez; Keyon Taravati; Uk Sok Shin; Timothy H McCalmont; Michael D Rosenblum
Journal:  J Am Acad Dermatol       Date:  2016-01-09       Impact factor: 11.527

4.  Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.

Authors:  George Plitas; Catherine Konopacki; Kenmin Wu; Paula D Bos; Monica Morrow; Ekaterina V Putintseva; Dmitriy M Chudakov; Alexander Y Rudensky
Journal:  Immunity       Date:  2016-11-15       Impact factor: 31.745

Review 5.  Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.

Authors:  Bin Shang; Yao Liu; Shu-juan Jiang; Yi Liu
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

6.  The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.

Authors:  Qing-Kun Song; Jun Ren; Xin-Na Zhou; Xiao-Li Wang; Guo-Hong Song; Li-Jun Di; Jing Yu; Amy Hobeika; Michael A Morse; Yan-Hua Yuan; Hua-Bing Yang; Herbert Kim Lyerly
Journal:  Oncotarget       Date:  2015-12-01

7.  The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers.

Authors:  Viriya Kaewkangsadan; Chandan Verma; Jennifer M Eremin; Gerard Cowley; Mohammad Ilyas; Sukchai Satthaporn; Oleg Eremin
Journal:  J Immunol Res       Date:  2017-08-23       Impact factor: 4.818

8.  FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer.

Authors:  Leandra Fiori Lopes; Roberta Losi Guembarovski; Alda Losi Guembarovski; Marina Okuyama Kishima; Clodoaldo Zago Campos; Julie Massayo Maeda Oda; Carolina Batista Ariza; Karen Brajão de Oliveira; Sueli Donizete Borelli; Maria Angelica Ehara Watanabe
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

Review 9.  The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yan Mao; Qing Qu; Xiaosong Chen; Ou Huang; Jiayi Wu; Kunwei Shen
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

Review 10.  Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.

Authors:  Jiafeng Shou; Zhigang Zhang; Yucheng Lai; Zhigang Chen; Jian Huang
Journal:  BMC Cancer       Date:  2016-08-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.